Area of research
Molecular Biology · Oncology
Research interest
Research interests include PARP inhibition in cancer therapy, DNA Repair Mechanisms, CRISPR and Genetic Engineering, and Cancer Genomics and Diagnostics.
NASP modulates histone turnover to drive PARP inhibitor resistance
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
ADP‐ribosyltransferases, an update on function and nomenclature
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
A decade of clinical development of PARP inhibitors in perspective
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response
The shieldin complex mediates 53BP1-dependent DNA repair
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer